ARTICLE | Clinical News
Anagrelide CR regulatory update
December 30, 2016 9:10 PM UTC
Galena said FDA confirmed that a Phase III trial comparing anagrelide CR vs. best available therapy in patients with essential thrombocythemia would be appropriate for an NDA submission using the 505(...
BCIQ Company Profiles